Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome

Anterior Resection Syndrome Clinical Trial

Status Not yet recruiting

Clinical Trial Summary

Poor functional outcomes has been reported inevitably, and up to 90% of the patients have experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But, currently there has been no specific treatment for ARS and symptom based empirical management is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has been revealed to be slowing the bowel movement and improving stool consistency and urgency.

We performed the clinical trial with using ramosetron (Irribow®) for the treatment of ARS

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anterior Resection Syndrome
• Syndrome

• NCT number: NCT02869984
• Study type: Interventional
• Source: Seoul National University Hospital
• Contact: Kyu Joo Park, MD, PhD
• Phone: +82-2-2072-2901
• Email: kjparkmd@plaza.snu.ac.kr
• Status: Not yet recruiting
• Phase: Phase 0
• Start date: August 2016